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Abstract 
 The purpose of this thesis is to describe some of the research I conducted in Dr. 
Markmann’s laboratory at Massachusetts General Hospital in the field of transplantation 
immunology.  The first portion provides background information on the immune system 
and its different components, eventually providing an in-depth look at regulatory T cells, 
and their role in transplant immunology.  The second portion of the thesis is dedicated to 
my experiments.  This part presents the materials and methods used, the previous 
findings that led to my experiments, the data analysis and results, and a conclusive 
discussion. 
 The research I did that is included in this thesis pertains to regulatory T cells.  It is 
believed that a potential pathway to prolonging allograft survival is to drive antigen-
specific CD4+Foxp3- T cells to convert to CD4+Foxp3+ T cells.  I studied the effects of 
retinoic acid (RA) and anti-CD45RB treatment on Foxp3 expression in CD4+ T cells.  
These studies were done using different lines of transgenic mice that provided models of 
antigen-specificity.  My in vitro data demonstrated that RA is capable of boosting TGF-
β-mediated Foxp3 upregulation in a synergistic manner and that anti-CD45RB is also 
able to increase Foxp3 expression.  In vivo RA experiments were inconclusive, and due to 
some misfortune and time constraints in vivo anti-CD45RB experiments were not 
conducted.   
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Introduction 
Organ and tissue transplantation are responsible for saving or improving the lives 
of thousands of patients annually, yet the science behind transplantation is far from being 
fully understood.  The largest hurdle when dealing with transplantation is not the surgical 
aspect, but rather preventing the rejection of the transplanted tissue or organ in the 
recipient.  Transplant immunology, the science behind transplantation and rejection, falls 
under the broader category of immunology, the study of the immune system.  The 
immune system protects our bodies from harmful elements in our environment, and it is 
largely responsible for our general well-being.  Transplant immunology has made 
significant strides in advancing transplant medicine over the last few decades, but there is 
much more to learn.  While scientists have discovered the tools necessary to wage war 
against rejection in immunosuppressant drugs, the ultimate goal is to win the war against 
rejection and make the life-long use of immunosuppressive therapy unnecessary by 
discovering new ways to establish prolonged non-reactivity against a transplant.   
 My introduction to transplant immunology began in 2009 when I spent the 
summer working in the Transplant Surgery Research Laboratory at Massachusetts 
General Hospital.  More specifically, I worked in Dr. James Markmann’s laboratory 
under the guidance of Dr. James Kim, Matt O’Connor, and Patrick Duff.  They taught me 
all of the experimental protocols that our laboratory utilizes, how to handle and skin graft 
mice, and how to analyze flow cytometry data.  After the summer of 2009, I continued to 
work in the laboratory two days a week during the fall and spring semesters of my junior 
year.  Towards the end of the spring semester, with knowledge that I would be working in 
the laboratory over the summer again, I decided that I would like to use research from the 
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laboratory to write my senior thesis.  Over the course of about a year and a half, the time 
I spent in the laboratory taught me a great deal about immunology and gave me great 
exposure to genuine medical and scientific research. 
 Much of the research I was involved with in Dr. Markmann’s laboratory 
concentrates on regulatory T cells (Tregs).  This research was aimed at understanding the 
mechanisms behind Treg-mediated tolerance and investigating the effects of 
pharmacological agents on regulatory properties of Tregs.  My experimental work, as it 
pertains to this thesis, was focused on using different pharmacological agents to increase 
Treg populations.  It was my intention to test different reagents both in vivo and in vitro; 
however, this past summer our laboratory encountered a major setback.  Our mouse 
colony room on our floor became contaminated with pinworm and unfortunately 
thousands of mice had to be euthanized.  This resulted in the termination of on-going in 
vivo experiments, as well as the blockage of future in vivo experiments.  Because of the 
lengthy animal testing, decontamination, and repopulation procedures, I did not have the 
time to carry out the proposed in vivo experiments.  This situation did teach me an 
important lesson about experimenting with live animals:  There is always an aspect of 
variability when working with live animals that sometimes results in unforeseen 
complications. 
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Background 
Immune System:  Innate and Adaptive 
 The immune system is a highly evolved, biological protection agency that guards 
the body against invading pathogens.  The immune system has evolved in such a way that 
a division of labor exists; there are the innate immune system and the adaptive immune 
system.  While these two components of the immune system have distinguishing features, 
they have evolved to work in concert, thereby increasing efficiency.  An invading 
pathogen’s first encounter is with the innate immune system, a set of constitutively 
present, nonspecific mechanisms aimed at quickly removing the pathogen.  If the innate 
system is not capable of clearing the pathogen within a few days, the adaptive immune 
system will then take over.  The adaptive immune system produces a more specific 
response through the recruitment of lymphocytes and the generation of antibodies.   
 The innate immune system has different layers of protection that a pathogen has 
to encounter before adaptive immunity becomes involved.  The first of these layers are 
anatomical barriers such as skin and mucous membranes, and the oils and mucous they 
produce.  The next component of innate immunity is phagocytosis.  Certain cell types, 
such as monocytes, macrophages, and neutrophils are responsible for clearing pathogens 
via phagocytosis.  Besides phagocytic cells, there are also soluble factors that can break 
down pathogens on their own, or aid in the induction of phagocytosis, a process called 
opsonization.  Lysozyme is an example of a soluble enzyme that destroys bacterial cell 
walls.  Other molecules such as mannose-binding lectin and C-reactive protein activate 
the complement system, which can lyse cells by disrupting cell membranes or opsonize 
the pathogen.  Both the phagocytic cells and the soluble molecules detect pathogens 
	  	  
	   7 
through the recognition of common microbial motifs called pathogen-associated 
molecular patterns, or PAMPs.  The detection of microbe-specific patterns allows for 
innate immunity to provide nonspecific protection, while also having perfect self-nonself 
discrimination due to the fact that the host does not express any pathogen-associated 
molecular patterns.  While most invading pathogens encounter and get cleared by the 
innate immune system before having to deal with the adaptive immune system, 
sometimes the body requires the help of the highly specific, diverse weapons of adaptive 
immunity.  (Reviewed in Kindt et al., 8, 9, 52-57) 
 Both the innate and adaptive immune systems become activated soon after an 
antigenic challenge, but it takes about five or six days for the adaptive immune system to 
make an impact.  The adaptive immune response is more specific and coordinated than 
the innate immune response.  The important features of adaptive immunity are antigenic 
specificity, diversity, immunologic memory, and self-nonself recognition (Kindt et al., 8-
9).  The ability of the adaptive immune system to distinguish between billions of unique 
antigens, going so far as to discriminate protein molecules differing in a single amino 
acid residue (Kindt et al., 12), is what is meant by antigenic specific and diversity.  The 
ability of adaptive immunity to “remember” an antigen it has responded to once allows 
for a quicker and more aggressive response with subsequent encounters.  Immunologic 
memory usually persists in the host for its lifetime, which means that adaptive immunity 
can provide lifelong protection against previously cleared pathogens, an example being 
the success of vaccination.  The adaptive immune system usually only attacks foreign 
antigens, which means it has the ability to distinguish between self and non-self.  The 
importance of this ability can be gleaned from the instances where a fault occurs in self-
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nonself discrimination; an error of this kind can lead to a wide range of autoimmune 
diseases and possibly even death.  (Reviewed in Kindt et al., 10-12)  
 
Lymphocytes and Antigen-Presenting Cells 
 The cells responsible for enabling adaptive immunity are 
lymphocytes and antigen-presenting cells (APCs).  There are two 
types of lymphocytes:  B cells and T cells.  Both B and T cells arise 
in the bone marrow; however, immature T cells migrate to the 
thymus to mature, where as B cells remain in the bone marrow to 
mature.  The aforementioned ability of the adaptive immune system 
to recognize billions of specific antigens comes from the enormous 
repertoire of unique cell surface receptors that B and T cells express.  
B cells express hundreds of thousands of antigen-binding receptors 
on their surface; the antigen-specificity of these receptors is conserved for a particular B 
cell clone, but differs from one cell clone to the next.  These receptors are membrane 
bound antibodies.  Activation of a naïve B cell by the binding of antigen to membrane 
bound antibody causes the proliferation of the B cell into both memory B cells and 
plasma cells.   Both types of daughter cells express the same antibody as the parent cell, 
except during affinity maturation.  The differences are that plasma cells secrete the 
antibody rather than having membrane bound antibody, and they have a much shorter life 
span than memory B cells.  (Reviewed in Kindt et al., 12-16) 
 Like the antigen-binding receptors that B cells express, T cells also express 
unique membrane bound antigen receptors called T-cell receptors (TCRs).  T cells are 
(Kindt et al., 2007) 
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also similar to B cells in the sense that each T cell expresses many TCRs all of the same 
antigen-specificity.  Two distinct subpopulations of T cells exist and are identified by the 
type of co-receptor associated with the TCR:  T helper cells and cytotoxic T cells, which 
express CD4 and CD8, respectively.  Another type of T cell especially pertinent to the 
experiments discussed later in this paper, and one that will be described in more detail 
later, is the regulatory T cell (Treg).  Tregs can be characterized by CD4 expression along 
with CD25 expression, but are best characterized by Foxp3 expression.   
 While there exist similarities between B cells and T cells, they are very different 
in the way their respective receptors bind antigen.  TCRs are unlike B cell membrane 
bound antibodies because they cannot directly bind free antigen.  They only appreciate 
antigen bound to major histocompatibility complex (MHC) molecules, of which there are 
two kinds.  Class I MHC molecules are expressed on the membranes of all cells, 
excluding red blood cells, and are responsible for presenting antigen to CD8+ cytotoxic T 
cells.  Class II MHC molecules are only expressed on APCs and present antigen to CD4+ 
T helper cells. (Reviewed in Kindt et al., 12-16)  
 Antigen-presenting cells are important cells that play a supporting role in 
activating the humoral and cell-mediated branches of the immune system via T helper 
cells.  There are generally considered to be three professional types of APCs:  dendritic 
cells, macrophages, and B cells.  APCs function by first internalizing antigen and then 
processing that antigen so it can be displayed on membrane bound class II MHC 
molecules.  The contact of T helper cell TCRs with the antigen-class II MHC complex on 
APCs, and the right co-stimulation, activates the T helper cell causing it to proliferate and 
differentiate.  APCs also produce cytokines that aid in the activation of T helper cells.  In 
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a similar fashion, cytotoxic T cells are activated when their TCRs interact with antigen-
class I MHC molecule complexes. (Reviewed in Kindt et al., 13-15, 34, 35) 
 The proliferation and differentiation of T helper cells produce both memory cells 
and effector cells.  When cytotoxic T cells become activated and divide they also produce 
memory cells and effector cells, but these effector cells are termed cytotoxic T 
lymphocytes (CTLs).  Effector cells are responsible for the different elements of the 
resulting immune response, while memory cells lay in wait to induce an immune 
response upon later exposure to the initial antigen.  When T helper cells differentiate into 
effector cells, they secrete cytokines that have an effect on various other cells involved in 
the immune response, hence their name.  The cytokines facilitate the activation of 
cytotoxic T cells, B cells, and macrophages among others.  Activated cytotoxic T cells in 
the form of CTLs monitor the body for tumor cells or infected cells and destroy them.  
Contrary to the role T helper cells play as a major stimulator of branches of the immune 
system, Tregs suppress the 
immune system as a protection 
against it becoming overactive or 
targeting self-antigen.   
Tregs act to regulate the 
adaptive immune response by 
suppressing the proliferation of 
antigen-reactive T cells and 
maintaining tolerance to self-
antigen.  There exists a need to                              (Kindt et al., 2007) 
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suppress self-reactive T cells due to failures of negative selection during the maturation 
of the T cells.  Tregs present in the periphery quell whatever autoimmune processes occur 
due to the self-reactive T cells that make it out of the thymus (Kindt et al., 406).  
Impaired Treg development or function is hypothesized to be a major cause of 
autoimmune and inflammatory diseases (Sakaguchi et al., 2008).  The role of Tregs as an 
inherent regulator of self-tolerance has implicated them as a very possible approach for 
mediating immune responses directed towards transplanted tissue.  Because Tregs and 
their involvement in the transplant setting are central to this paper I will present a more 
detailed account of them in the following section. (Reviewed in Kindt et al., 13-15, 34, 
35) 
 
Regulatory T Cells 
The idea of an immune system-suppressing lymphocyte population was around 
for many years before Sakaguchi and co-workers, in 1985, provided the first 
experimental evidence for such a population of lymphocytes.  Sakaguchi et al. showed 
that the depletion of Lyt-1 T cells from splenocytes transferred to immunodeficient 
recipients induced organ-specific autoimmune diseases (Sakaguchi et al., 1985).  Ten 
years later, Sakaguchi et al. performed a similar experiment with similar results, but 
depleted a more specific population of T cells defined by cell surface marker CD25 
(Sakaguchi et al., 1995).  These two experiments revealed that a population of cells 
contained within the depleted fractions had a role in maintaining self-tolerance.  The 
characterization of the Treg population as CD25+ facilitated more research in the field 
because it enabled for the population of interest to be easily identified and isolated. 
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Dual expression of CD4 and CD25, found on about 5% to 10% of peripheral T 
cells (O’Garra and Viera, 2003), defined the Treg subset until progress was made in 
understanding the mechanisms governing their development and function.  While CD4 
and CD25 expression remain good markers for Tregs, they are now best defined by the 
expression of Foxp3.  Foxp3 (forkhead box P3) is a transcription factor encoded by the 
Foxp3 gene, which is specifically expressed by Tregs (O’Garra and Viera, 2003).  The 
Foxp3 gene was discovered in scurfy mice as the mutant gene causing the lethal 
lymphoproliferation and autoimmunity that only male scurfy mice exhibit because it is x-
linked (Sakaguchi et al., 2008).  The similarity between the symptoms of scurfy mice and 
the symptoms of mice depleted of Tregs gave researchers reason to suspect that Foxp3 
has a role in Treg function (Sakaguchi et al., 2008).  This eventually led to findings that 
Foxp3 is central to the development and function of Tregs (O’Garra and Viera, 2003; de 
Lafaille and Lafaille, 2009; Sakaguchi et al., 2008); in its absence, Tregs do not develop 
and loss of regulation ensues (Hori et al., 2003).  Additionally, retroviral transduction of 
Foxp3 to non-regulatory T cells confers suppressive and regulatory ability (Sakaguchi et 
al., 2008). 
The peripheral population of Tregs is comprised 
of two subsets of Tregs:  natural Tregs (nTregs), and 
adaptive or induced Tregs (iTregs).  nTregs are 
produced in the thymus from a population of immature 
thymocytes that express TCRs with an intermediate 
avidity for self-antigen-class II MHC molecule 
complexes (Kronenberg and Rudensky, 2005; Kindt et      (de Lafaille and Lafaille, 2009) 
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al., 406).  iTregs differentiate from naïve, mature CD4+Foxp3- T cells already in the 
periphery; they normally develop in response to chronic inflammation and 
subimmunogenic levels of antigen (de Lafaille and Lafaille, 2009; Kretschmer et al., 
2008).  The activation of Tregs to immunoregulate the activity of CD4+ T cells is 
antigen-specific due to the fact that Tregs are activated through the TCR (Kindt et al., 
263).  However, once activated, Tregs can suppress effector cells of different antigen-
specificity (Thornton and Shevach, 2000).  
 Treg-mediated suppression plays a large role in the immune system by affecting 
the dynamics of immune reactions and tolerance.  It has become clear that the effect of 
Tregs on effector cells is essential for controlling immune responses and for becoming 
tolerant or intolerant to self and non-self antigens (Sakaguchi et al., 2008).  This finding 
has led to considerable amounts of research aimed towards more fully understanding 
Tregs.  This research focuses on manipulating Treg populations and defining their 
suppression mechanisms with the goal of finding therapeutic uses for Tregs. 
Without functioning Tregs, tolerance to self-antigens breaks down and the 
immune system becomes susceptible to developing autoimmune tendencies (Sakaguchi et 
al., 2008).  However, when Tregs are depleted in a rodent model, the T cell response 
against tumor-associated antigens is increased (Shimizu et al., 1999).  If this knowledge 
is applied to humans, in the case of a patient battling cancer, the enhanced immunity 
against the tumor may outweigh negative side effects associated with Treg depletion.  
Unlike the strategy of depleting Tregs to deal with cancer, many therapeutic options 
being investigated involve increasing Treg numbers or enhancing their function.  Aside 
from enhancing Treg function to treat autoimmune diseases and severe allergies, the 
	  	  
	   14 
potential for this kind of therapy to be used as an anti-rejection protocol after 
transplantations is promising.     
Understanding the mechanisms of Treg-mediated suppression is important to the 
process of developing safe Treg-based treatment regimens for human application.  
Although a complete mapping of the pathways affecting Treg function has not yet been 
achieved, years of research have begun to elucidate some of the molecular role players 
involved with Tregs.  Interestingly, several molecules have been implicated depending on 
whether the Tregs were in vitro or in vivo, the reasons for which remain unclear.  Thorton 
et al. demonstrated that the inhibition of IL-2 transcription is involved in the suppression 
mechanism in vitro (Thornton and Shevach, 1998).  By providing IL-2 or anti-CD28 to a 
co-culture of T effector cells and Tregs the effector cells overcame the Treg-mediated 
suppression, and when removed the effectors returned to a state of anergy (Thornton and 
Shevach, 1998).  In vitro suppression requires cell-to-cell contact, as demonstrated by the 
lack of Treg function across a semi-permeable membrane (Thornton and Shevach, 1998).  
Several molecules have been linked to 
normal Treg function in vivo:  CTLA4, IL-10, 
TGF-β, and GITR, among others.  By blocking 
CTLA4 ligation the regulatory ability of Tregs is 
disrupted.  Additionally, Treg-expressed GITR 
binding to its ligand impedes Treg function, and 
has the secondary effect of enhancing effector 
responses.  Studies using transplantation and autoimmunity models have also shown that 
the cytokines IL-10 and TGF-β are needed for Treg-mediated suppression of skin-
          (Wood and Sakaguchi, 2003)  
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allograft rejection and prevention of inflammatory bowel disease (IBD), respectively.  
(Wood and Sakaguchi, 2003) 
In addition to work studying the role of molecules such as cytokines, growth 
factors, and cell-associated receptors in Treg-mediated immunoregulation, the interaction 
of Tregs with APCs is a topic of interest.  In a normal setting, Tregs downregulate 
dendritic cell expression of CD80 and CD86, co-stimulatory molecules necessary for T 
cell activation (Wing et al., 2008).  But when Tregs lack CTLA4, achieved via a CTLA4 
conditional knockout, they fail to downregulate dendritic cell expression of CD80 and 
CD86 (Wing et al., 2008).  This lends itself to the possibility that Tregs suppress T 
effector cells indirectly by altering the influence of APCs on the effector cells. 
Other studies have shown that instead of Tregs altering APCs, APCs can be 
involved in blocking Treg function.  This evidence falls under the umbrella of research 
investigating the possible mechanisms through which the innate immune response may 
control Treg function.  APCs bridge the transition from innate to adaptive immunity, so it 
makes sense that APCs, in order to initiate an adaptive immune response, could have an 
inhibitory effect on Tregs.  It has been shown that APCs activated through Toll-like 
receptors 4 and 9 (TLR-4 and TLR-9), which have roles in innate immunity and are 
sensitive to bacterial microbes (Kindt et al., 62-64), induced these APCs to secrete IL-6, 
which hindered Treg function (Pasare and Medzhitov, 2003).  Along these lines, it has 
been shown in vivo that ligation of CpG to TLR-9 prevents long term allograft survival 
and intragraft recruitment of Tregs (Chen et al., 2006). 
Prior to starting my research, the researchers I worked with observed diminished 
Treg function in an acute transplant setting as compared with an established transplant 
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setting, where the graft has survived for a month (Kim et al., 2009).  It was hypothesized 
that this effect on Treg function was caused by innate immunity activation resulting from 
the acute transplantation procedure.  They coined this Treg silencing “counter-
regulation,” and found that in vivo counter-regulation is associated with reduced Foxp3 
expression (Kim et al., 2009).  From the knowledge that Treg function may be negatively 
affected in the transplant setting, I conducted research investigating the application of 
retinoic acid (RA) and anti-CD45RB in the transplant setting so as to oppose counter-
regulation by upregulating Foxp3 expression in CD4+ T cells.     
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Materials and methods 
Animals: 
For in vitro RA experiments, Balb/c mice (Jackson Laboratory, Bar Harbor, ME) were used as a 
source of APCs.  TS1xThy1.1 transgenic mice were used as a source of CD4+ T effector cells.  
TS1 transgenic mice produce CD4+ T cells with antigen specificity for the immunodominant 
epitope (S1) of influenza hemagglutinin (HA) in the context of MHC II IEd (Kirberg et al., 1994).  
TS1xThy1.1 mice express CD90.1 on T cells as opposed to CD90.2, which is expressed by 
Balb/c; this affords the opportunity to selectively analyze certain cell populations.   
 
For in vitro anti-CD45RB experiments, Thy1.1 transgenic mice were used as a source of APCs.  
TS1xHA28 mice were used as a source of CD4+ T effector and Treg cells. 
 
TS1, Thy1.1, and HA28 transgenic lines are maintained as hemizygotes backcrossed with 
BALB/c mice.  All animals are maintained in a pathogen-free environment under IACUC 
approved protocols. 
 
Reagents: 
S1 (HA) peptide (Massachusetts General Hospital, Boston, MA) is a high affinity agonist for the 
6.5 TCR of TS1 transgenic mice (Jordan et al., 2001). 
 
Anti-CD3/CD28 beads (Invitrogen, Carlsbad, CA) induce extensive T cell proliferation by 
providing an activation signal and co-stimulatory signal via interaction with the TCR-CD3 
complex and the CD28 molecule, respectively (Trickett and Kwan, 2003). 
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Retinoic acid (RA) (Sigma-Aldrich, Saint Louis, MO) is a metabolite of vitamin A that can 
promote TGF-β-dependent Treg cell differentiation (Mucida et al., 2007). 
 
TGF-β (Bio X Cell, West Lebanon, NH) is a cytokine that drives the generation of Tregs (Fu et 
al., 2004). 
 
T Cell Purification: 
Spleen and lymph nodes were harvested and processed into a single-cell suspension by passage 
through a 70 µm cell strainer (Becton-Dickinson, Franklin Lakes, NJ).  This cell suspension was 
resuspended in red blood cell lysis buffer (Sigma-Aldrich, Saint Louis, MO) for 5 minutes and 
then sorted.  The CD4+ and CD25+ T cell fractions were isolated using a MACS® CD4+CD25+ 
Regulatory T Cell Isolation Kit (Miltenyi Biotec, Germany). 
 
CFSE Labeling: 
CFSE (Invitrogen, Carlsbad, CA) is a fluorescent dye used to monitor lymphocyte proliferation 
by the halving of CFSE fluorescence with each cell division.  A single-cell suspension of 
splenocytes and lymphocytes was prepared at a density of 107 cells/mL in MEM (Mediatech-
Cellgro, Manassas, VA).  An equal volume of 5 mM CFSE diluted to 1:1200 in MEM was added 
and the cells were incubated for 5 minutes at 37C.  The reaction was stopped by adding a volume 
of FBS (Mediatech-Cellgro, Manassas, VA) equal to the original volume of the cell suspension.  
Two washes were then performed with MEM containing 5% FBS. 
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In vitro conversion assays: 
For RA experiments, 4 x 105 CFSE-labeled, purified CD4+CD25- T cells from TS1xThy1.1 
mice were cultured with 2 x 105 irradiated Balb/c splenocytes, 20 µg S1 peptide or 2 µl anti-
CD3/CD28 beads, and different concentrations of RA (20 nM, 100 nM, 500 nM) and TGF-β (0.5 
ng/mL, 2.0 ng/mL) for five days at 37C.  Cells were grown in complete 10% RMPI 1640 
(Sigma-Aldrich, Saint Louis, MO).  
 
For anti-CD45RB experiments, 4 x 105 CFSE-labeled, purified CD4+CD25- T cells from 
TS1xHA28 mice were cultured with 2 x 105 irradiated Thy1.1 splenocytes, 20 µg S1 peptide or 2 
µl anti-CD3/CD28 beads, and different concentrations of anti-CD45RB (2 µg/mL, 10 µg/mL, 20 
µg/mL) for five days.  Cells were grown in complete 10% RMPI 1640.  
 
In vivo conversion assays: 
For the RA experiment, HA skin was used to set up established skin allografts (those that have 
healed for 30 days) on Balb/c mice using the skin grafting protocol below.  Once the grafts were 
fully established, 3 x 106 CD4+CD25- effectors from TS1xThy1.1 mice were adoptively 
transferred to each mouse via intravenous injection to the dorsal penile vein.  One group (n=3) 
was grafted and treated with RA (300 µg/mouse), dissolved in a 1:1 ratio of DMSO (Mediatech-
Cellgro, Manassas, VA) and soybean oil (Sigma-Aldrich, Saint Louis, MO), every other day.  
Another group (n=3) was grafted but received no RA.  Two controls, non-grafted with RA (n=1), 
and non-grafted without RA (n=1), were also set up.  At 7 and 14 days, mice were sacrificed to 
harvest the draining lymph nodes and spleen.  The harvested cells were then analyzed for 
proliferation and Foxp3 expression of the adoptively transferred cells.   
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Skin Grafting: 
The donor mice were euthanized by cervical dislocation after first anesthetizing them with 
isofluorane (Henry Schein, Melville, NY).  They were shaved and the skin was prepared by 
cutting it into roughly 1 cm2 pieces.  The fatty layers attached to the skin were scrapped off using 
a number 10 scalpel (Becton-Dickinson, Franklin Lakes, NJ).  While preparing the recipient 
mice, these pieces of skin were kept in PBS (Mediatech-Cellgro, Manassas, VA) on ice.  The 
recipient mice were anesthetized with an intraperitoneal injection of 0.5 mL avertin (20 mg/mL) 
(Sigma-Aldrich, Saint Louis, MO) and then shaved.  The graft sites, dorsolateral to the chest and 
over the ribs, were prepared by cutting off a square of skin equal to the size of the graft.  The 
donor grafts were then sutured in place, with one suture at each corner and each side, using 5-0 
vicryl sutures (Johnson & Johnson, Somerville, NJ).  The graft was then covered with gauze, a 
bandage, and medical tape.  This procedural method is adapted from the technique of Billingham 
and Medawar (Billingham and Medawar, 1951).  Grafts were deemed rejected when 75% or 
more of the graft was lost.  
 
Flow Cytometric Analysis: 
Cells were washed in FACS buffer and stained with the following antibodies from eBioscience 
(San Diego, CA):  anti-CD4 PE-Cy7, anti-Thy1.1 PacificBlue, anti-Foxp3 APC, and 6.5 biotin.  
The 6.5 biotin was followed by strepavidin-APC-A750 (Invitrogen, Carlsbad, CA) secondary to 
detect the transgenic TS1 TCR (Kirberg et al., 1994; Jordan et al., 2001).  Flow cytometric 
analysis was performed on a BD Immunocytometry System LSR II (Becton-Dickinson, San Jose, 
CA).  LSR II data acquisition and analysis were performed using Diva and FlowJo Software 
(Tree Star, Stanford, CA).
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Experimental Logic and Results 
The researchers I worked with previously demonstrated that iTreg generation is necessary 
for graft tolerance (Figure 1).  This work entailed adoptively transferring either CD4+CD25- 
wild-type or scurfy T cells into skin-grafted mice.  Half the mice were treated with rapamycin, an 
immunosuppressant that induces 
de novo generation of alloantigen-
specific Foxp3+ Tregs (Gao et al., 
2007).  Rapamycin prolongs graft 
survival with wild-type cells but 
not scurfy cells, because scurfy 
cells are unable to become 
Foxp3+ (Brunkow et al., 2001).  
It has also been shown that T 
helper cells upregulate Foxp3 
upon exposure to TGF-β (Chen et 
al., 2003), and that this TGF-β-mediated conversion from Foxp3- cells to Foxp3+ cells can be 
intensified by retinoic acid (RA), a metabolite of vitamin A (Mucida et al., 2007). Although RA 
has positive effects on TGF-β-mediated Foxp3 expression, it has been shown that in the absence 
of TGF-β, RA is unable to provide conversion (Mudica et al., 2007).  To expand upon these 
findings, my work investigated the effects of RA, as well as those of anti-CD45RB, on Tregs as a 
means to achieve allograft prolongation. 
Prior to in vivo experiments, different in vitro assays were set up to apply what is known 
about RA and TGF-β to an allograft setting.  An in vitro assay investigating the effects of RA 
Figure 1.  Rapamycin-mediated Foxp3 upregulation prolongs allograft 
survival in normal B6 mice, but not in scurfy mice, which carry a 
mutant Foxp3 gene.  A shows the change from 100% graft rejection 
around 20 days for wild-type cells without rapamycin treatment to 
100% graft survival at 60 days for the same cells with treatment; 
treatment of scurfy cells produced no significant change in graft 
survival.  The histograms in B quantitatively show rapamycin’s effect 
on Foxp3 upregulation in B6 and Surfy cells. 
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without TGF-β in an allograft setting was followed up with an in vivo experiment of the same 
style.  My work also entailed in vitro experiments that tested not only whether the synergistic 
effect of RA and TGF-β on Foxp3 expression existed in the allograft setting, but also whether 
anti-CD45RB could enhance Foxp3 expression.  Unfortunately, these later in vitro experiments 
were not followed up by in vivo equivalents because our facility that housed post-procedural 
mice was contaminated with pinworm; this contamination halted all of our laboratory’s in vivo 
experiments.  The time course of clearing the contamination and getting the facility back in order 
never allowed me to conduct these experiments.   
 
Does retinoic acid increase the expression of Foxp3 in TS1+CD4+CD25- T cells in an in vitro 
allograft setting? 
An initial assay was set up to test the capacity of RA to mediate iTreg conversion in the 
absence of TGF-β.  The results showed that RA did not have a significant effect on the 
expression of Foxp3 in TS1+CD4+CD25- T cells stimulated with cognate HA (S1) peptide or 
anti-CD3/CD28 beads (Figure 2).  The only detectable effect was that RA, at all concentrations, 
decreased the percentage of Foxp3+ cells compared to the percentage when there was no RA 
(Figure 2).  Although RA was unable to influence conversion, it did affect the proliferation of 
the stimulated cells.  As the concentration of RA was increased, the proliferation of cells, 
independent of how they were stimulated, was reduced (Figure 2).  For example, there was 
41.5% proliferation when the cells were stimulated with S1 peptide and 20 nM RA, but only 
22.7% proliferation when stimulated with S1 peptide and 500 nM RA (Figure 2).  It is important 
to note this, because as the proliferation of activated T cells decreases, the ratio of Tregs to T 
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effector cells increases.  This ratio is important when examining the ability to of a Treg 
population to suppress an immune response.   
 
Is the administration of RA in vivo capable of prolonging allograft survival by mediating the 
conversion of iTregs? 
 Proceeding from the in vitro work, an 
adoptive transfer model was used to study iTreg 
generation in vivo.  This model is valuable for 
studying Tregs in a transplant setting because it 
involves an immunocompetent host and a highly 
Shoul
Figure 2.  The addition of RA to stimulated T effector cells in vitro does not upregulate the conversion of these 
effectors to Tregs; RA has a negligible effect on Foxp3 expression.  In both settings of activation, with S1 peptide and 
beads, the proliferation of effector cells decreases as the concentration of RA increases.  The control of unstimulated 
cells is not shown.    
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specific rejection process (Lee et al., 2004). TS1xThy1.1 CD4+CD25- T cells were adoptively 
transferred to BALB/c mice transplanted with HA-expressing skin allografts.  Established 
allografts were used to avoid the negative, inflammation-mediated side effects of the 
transplantation process on Tregs.  Levels of Foxp3 expression in the TS1xThy1.1 cells were 
compared at 7 and 14 days post-adoptive transfer in mice receiving RA treatment every other 
day versus mice receiving no RA treatment.  Both draining lymph nodes (DLNs) and spleens 
were harvested and examined for the upregulation of Foxp3.  Before being transferred into the 
host mice, these cells were CFSE-labeled, which also allowed for their proliferation to be tracked.    
Although the in vitro data for RA treatment showed that it was unable to influence Treg 
conversion alone, it was thought that perhaps RA treatment in vivo could elicit Foxp3 
upregulation through endogenous mechanisms irreproducible in vitro.   Unfortunately, our in 
vivo data is not conclusive in showing that RA has a beneficial effect on upregulating Foxp3 
expression in CD4+CD25- T cells from DLNs of mice receiving HA-expressing skin allografts.  
Figure 3.  Treatment with exogenous RA does not drive the generation of iTregs from graft-reactive T cells in vivo.  
These graft-reactive CFSE-labeled CD4+CD25- T cells were adoptively transferred into mice 30 days post-transplant.  
Both proliferation and conversion remained fairly consistent, exhibiting RA’s lack of effect.  Flow shows DLN at 7 
days post-adoptive transfer.  The bar graph at right shows fold-increase in conversion from a sample size of n=4; this 
data was found to be statistically insignificant.  
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For example, as Figure 3 shows, at 7 days post-adoptive transfer, the iTreg conversion in the 
DLNs of a mouse that received RA treatments and one that did not was 1.2% and 1.58%, 
respectively.  The DLN data from the day 7 time point was determined to be statistically 
insignificant, and data from splenocytes and the day 14 time point are not shown.  This 
experiment shows, consistent with the in vitro experiment, that treatment with only RA does not 
help conversion, and may instead hinder conversion.   
 
Do retinoic acid and TGF-β synergistically increase the conversion of CD4+Foxp3- T cells to 
Foxp3+ Tregs in an in vitro allograft setting? 
To expand upon these findings, the cumulative effect of RA together with TGF-β was 
studied in an in vitro assay resembling a transplant setting.  Purified CFSE-labeled CD4+CD25- 
T cells from TS1xThy1.1 mice upregulated Foxp3 expression when stimulated by either S1 
peptide or anti-CD3/CD28 beads in the presence of RA and TGF-β.  Early setups of this assay 
showed that RA boosted TGF-β-mediated Foxp3 expression in an additive fashion.  After fine-
tuning the assay with regard to the concentrations of RA and TGF-β, we were able to produce 
results that showed Foxp3 upregulation is enhanced by TGF-β and RA in a synergistic fashion.  
In other words, the upregulation of Foxp3 due to RA combined with TGF-β was much better 
than the sum of upregulation seen from each reagent alone.   
The most favorable results were elicited when 20 nM RA was co-introduced with 1 
ng/mL TGF-β; this finding held true for cells stimulated with anti-CD3/CD28 beads and those 
stimulated by S1 peptide (Figure 4).  Aside from the combination of RA and TGF-β 
synergistically upregulating Foxp3, together they greatly reduced the proliferation of the T 
effectors, thereby increasing the ratio of Tregs to effectors (Figure 4).  Under S1 peptide 
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stimulation with just RA this ratio was 0.053:1, and with just TGF-β it was 0.174:1, but together 
RA and TGF-β caused the ratio to jump to 0.489:1.  As mentioned earlier, this ratio is important 
to the dynamics of an immune response.  In both settings of stimulation, the addition of only 
TGF-β elicited slight improvement to Foxp3 expression (Figure 4), where as the addition of only 
RA produced results similar to those from the first experiment discussed (Figure 2).  
Is anti-CD45RB able to induce Treg generation through upregulation of Foxp3 expression in an 
in vitro allograft setting? 
 It is well documented that anti-CD45RB is capable of prolonging allograft survival in 
vivo.  This has been demonstrated in murine models of islet allograft (Auersvald et al., 1997), 
renal allograft (Lazarovits et al., 1996), and cardiac allograft (Deng et al., 2007).  CD4+ T cells 
express varying levels of CD45RB.  T effectors fall within the CD4+CD45RBhigh subset, while 
Figure 4.  TS1xThy1.1 CD4+CD25- T cells show the synergistic effect of RA and TGF-β on Foxp3 expression after 
5 days in culture with S1 peptide or anti-CD3/CD28 bead stimulation.  These two reagents also cause a strong 
reduction in T effector proliferation. 
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Tregs fall within CD4+CD45RBlow subset (Gregori et al., 2005). It has been suggested that the 
immunomodulatory ability of anti-CD45RB to prolong allograft survival results from the 
antibody’s effect on these cell populations (Gregori et al., 2005).  By depleting 
CD4+CD45RBhigh effectors with anti-CD45RB, the ratio of CD4+CD45RBlow to 
CD4+CD45RBhigh T cells increases (Luke et al., 2003).  My study sought to determine, aside 
from increasing this ratio, whether treatment with anti-CD45RB can induce Treg conversion 
through the upregulation of Foxp3. 
 CD4+CD25+ and CD4+CD25- cells sorted from TS1xHA28 mice were CFSE-labeled, 
stimulated, and cultured for 5 days with differing concentrations of anti-CD45RB.  The in vitro 
treatment with anti-CD45RB produced promising results.  Increasing concentrations of anti-
CD45RB caused slight increases in Foxp3 expression in the CD4+CD25- cells; this pattern of 
results was similar for S1 peptide and anti-CD3/CD28 bead stimulation (Figure 5).  It is 
interesting to note, however, that the proliferation of the cells was affected differently depending 
on the mode of stimulation.   Cells stimulated with anti-CD3/CD28 beads saw a decrease in 
proliferation, but cells stimulated with S1 peptide did not (Figure 5).  Perhaps the mode of 
stimulation affected the ability of anti-CD45RB to deplete CD4+CD45high cells.   
The upregulation in Foxp3 expression seems to be the result of iTreg generation as 
opposed to the proliferation of nTregs, but only for the cells stimulated with S1 peptide.  This is 
because the CD4+CD25+ cells stimulated with S1 peptide did not proliferate, however, these 
same cells stimulated with beads experienced relatively robust proliferation (Figure 6).  Similar 
to the way that proliferation of CD4+CD25- T cells stimulated with beads decreased with anti-
CD45RB treatment, CD4+CD25+ cells stimulated with beads also saw a reduction in 
proliferation as the concentration of anti-CD45RB was increased (Figure 6).   
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Figure 5.  TS1xHA28 CD4+CD25- T cells in culture show a promising reaction to treatment with anti-CD45RB.  
As the concentration of anti-CD45RB added to culture increases from 2 µg/mL to 10 µg/mL so too does the 
expression of Foxp3.  Proliferation remains relatively constant for cells stimulated with S1 peptide, but decreases for 
cells stimulated with beads.   
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Figure 6.   TS1xHA28 CD4+CD25+ T cells stimulated with S1 peptide do not proliferate with or 
without anti-CD45RB.  When stimulated with beads, there is strong proliferation, yet this proliferation 
gets worse as the concentration of anti-CD45RB increases.    
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To expand upon this data, I sought to reinforce the results showing anti-CD45RB 
stimulated iTreg generation by using TS1xMoh transgenic mice that have GFP-linked Foxp3 
expression.  This characteristic allows for the cells to be sorted for Foxp3- cells with 99% 
certainty.  If this experiment showed an increase in Foxp3 expression after in vitro culture with 
the same conditions as the experiment above, then it could be concluded with 99% certainty that 
none of it was due to the proliferation of nTregs from the starting population.  Unfortunately, 
multiple repeats of this experiment were all failures; the data served to neither support nor refute 
the finding that anti-CD45RB was able to increase Foxp3 expression through iTreg generation.  
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Discussion 
 Tregs have great potential for clinical application in transplantation patients as a way to 
induce tolerance and achieve allograft survival without the use of adverse immunosuppressant 
drugs.  But in order to make the leap from laboratory experimentation to clinical experimentation, 
much more needs to be understood concerning the most appropriate ways for Tregs to be applied, 
and the potential side effects of Treg-related treatments.  The experiments in this paper expanded 
upon previous studies demonstrating the effects of pharmacological agents on iTreg conversion 
by testing for these effects in an allograft setting.  
 My studies testing the effects of RA on iTreg conversion were intended to expand upon 
data showing that RA improves TGF-β-mediated Foxp3 expression (Mucida et al., 2007).  The 
results of my in vitro assays confirmed that not only does RA act synergistically with TGF-β to 
convert effector cells to iTregs, but also that it can do so in an allograft setting.  The mechanisms 
underlying this effect are still unclear although there is much speculation.  Theories suggesting 
that RA interferes with cytokines that block iTreg conversion have begun to accumulate 
supporting data; these theories differ in what cytokines are hypothesized to be involved (Hill et 
al., 2008). 
The in vitro assays with RA, both with and without TGF-β, showed an increase in the 
ratio of Tregs to T effectors as the concentration of RA added was increased.  For the assay 
examining the role of RA alone, the increased ratio was the result of a decrease in proliferation 
rather than an increase in Foxp3 expression.  With the assay of RA combined with TGF-β, the 
increased ratio was the result of both decreased proliferation and synergistically increased iTreg 
conversion.  Treatment with TGF-β alone and RA alone both caused small decreases in 
proliferation, but when combined, there was a significant decrease in proliferation.  A favorable 
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ratio of Tregs to T effectors is important for normal Treg function.  When this ratio is increased, 
data suggests that tolerance induction may be achieved (Bloom et al., 2008; Chung et al., 2007).  
An important expansion of this study could be to test the iTregs for regulatory function by setting 
up a suppression assay.  It is important that iTregs generated from the increase in Foxp3 
expression retain their regulatory activity, because if not, they become insignificant.  While iTreg 
generation has been implicated in various transplant tolerance protocols, the laboratory group I 
was part of recently demonstrated that tolerance could exist in the absence of iTregs (Kim et al., 
2011). 
 Although my in vivo work was an experimental failure, and it could not be repeated due 
to the pinworm incident, the potential for RA treatment to cause iTreg conversion in vivo, and 
prolong allograft survival still exists.  The experiments I was able to set up involved established 
skin grafts, but RA may also have the potential to be therapeutic in an acute transplant setting, by 
impeding counter-regulation.  The researchers I worked with have hypothesized that during 
counter-regulation a reduction in Foxp3 levels following innate activation may cause Tregs to 
transdifferentiate to pro-inflammatory Th17 cells, a subset of T helper cells.  RA, aside from 
boosting TGF-β-mediated iTreg conversion, has also been shown to reduce TGF-β-mediated 
differentiation of Th17 cells (Mucida et al., 2007).  So, if the hypothesis that transdifferentation 
occurs proves to be the case, then RA treatment peri-transplant may be able to quell the effects of 
counter-regulation by preserving Foxp3 expression, therefore increasing allograft survival. 
 My data from the studies of anti-CD45RB is in line with the RA studies in that it 
provided some good evidence of a reagent capable of upregulating Foxp3 expression in an 
allograft setting.  The results show a gradual increase in Foxp3 expression as the concentration of 
anti-CD45RB is increased, but more concentrations should be tested to see whether this pattern 
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of expression continues, tapers off, or becomes toxic.  Anti-CD45RB has been demonstrated to 
prolong allograft survival and induce tolerance in different models of transplantation (Auersvald 
et al., 1997; Lazarovits et al., 1996; Deng et al., 2007).  However, the mechanisms underlying 
this induction of tolerance are not well understood, and therefore under scrutiny. 
The researchers that I worked with have begun to elucidate some interesting 
immunological mechanisms that play a role in anti-CD45RB-induced tolerance.  They first were 
able to show, in a model using heart allografts, that this kind of tolerance was thymus-dependent 
because of the necessity that thymus-derived Tregs are generated (Deng et al., 2006).  Deng et al. 
also made the interesting observation that anti-CD45RB-induced tolerance required B cells; this 
study also used heart allografts (Deng et al., 2007).  This finding opens the door to questions 
concerning the involvement of B cells in transplant tolerance, especially when considering work 
from other areas of immunology that demonstrate B cell populations with regulatory function 
(Mizoguchi and Bhan, 2006).  This population, labeled “Bregs,” has become a hot topic in 
transplant immunology research, and is now the focus of much of the research in the laboratory I 
worked in.  Breg research has not eclipsed the importance of Tregs, but may hold some of the 
answers needed to more fully understand the mechanisms of Tregs, and may help lead to the 
therapeutic application of Tregs in clinical transplantation.  
In summary, my studies found that both RA, in the presence of TGF-β, and anti-CD45RB 
are able to increase Treg populations in vitro through the upregulation of Foxp3 expression and 
induction of iTreg generation.  While I was unable to conduct as much in vivo research as I 
would have liked, the in vivo work I did do allowed me to learn technical research skills that I 
can apply later in my career.  Research in this field takes time and patience, so while my 
experimentation may have been limited, and my results undeserving of a Nobel Prize, the 
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entirety of the experience, from the research to writing the thesis, was still the most rigorous and 
educational experience of my college career.    
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